Phase II trial of intravenous (IV) meloxicam for the treatment of pain following open abdominal hysterectomy. is published in Anesthesia & Analgesia. Recro Pharma.

Recro Pharma, Inc. announced the publication of previously reported Phase II clinical data for intravenous (IV) meloxicam for the treatment of pain following open abdominal hysterectomy. The article, titled �Analgesic Efficacy and Safety of Intravenous Meloxicam in Subjects with Moderate-to-Severe Pain After Open Abdominal Hysterectomy: A Phase II Randomized Clinical Trial,� was published online in Anesthesia & Analgesia.

�These results from our Phase II trial evaluating IV meloxicam for the management of moderate to severe pain following abdominal hysterectomy surgery highlight IV meloxicam�s analgesic effect, coupled with a favorable safety and tolerability profile, in a soft tissue surgical model,� said Stewart McCallum, M.D., Chief Medical Officer of Recro Pharma. �Additionally, these data provide supportive evidence suggesting IV meloxicam�s ability to reduce the need for rescue opioid consumption, a critical need in today�s postoperative pain treatment landscape.�